Abstract
Purpose
The blood-brain barrier can prevent circulating tumor DNA (ctDNA) derived from the central nervous system from entering the blood making it challenging to evaluate molecular features of leptomeningeal metastasis (LM). Accordingly, we sought to systematically compare the diagnostic power or significance of ctDNA derived from cerebrospinal fluid (CSF) compared to plasma ctDNA in patients with LM.
Methods
A systematic review and meta-analysis was performed under the PRISMA guideline. We used PubMed, EMBASE, and the EuroPMC to search the literature using combinations of the following terms: circulating tumor DNA, ctDNA, circulating tumor cell, brain metastasis, leptomeningeal metastasis, outcome(s), and prognosis. We included all available English language studies that compared the diagnostic significance of CSF derived and serum ctDNA. All eligible studies level of bias was assessed using the New Castle Ottawa Scale (NOS).
Results
Our meta-analysis from 6 included studies (n = 226) that confirmed the diagnostic power of liquid biopsies in detecting genomic alteration is better when taking a CSF-derived samples than from the plasma (RR 1.46 [0.93; 2.29]; I2 = 92%; p-value < 0.01).
Conclusion
CSF ctDNA is better at describing molecular landscape for LM; such an understanding may ultimately help inform patient treatment and responses to therapy.
Similar content being viewed by others
Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.
Reference(s)
Valiente M, Ahluwalia MS, Boire A et al (2018) The Evolving Landscape of Brain Metastasis. Trends Cancer 4:176–196. https://doi.org/10.1016/j.trecan.2018.01.003
Choi W, Cho Y, Park S-Y et al (2021) A nanowire-based liquid biopsy method using cerebrospinal fluid cell-free DNA for targeted management of leptomeningeal carcinomatosis. J Cancer Res Clin Oncol 147:213–222. https://doi.org/10.1007/s00432-020-03324-5
Xu Q, Ye L, Huang L et al (2021) Serum exosomal miRNA might be a Novel Liquid Biopsy to identify Leptomeningeal Metastasis in Non-small Cell Lung Cancer. OTT Volume 14:2327–2335. https://doi.org/10.2147/OTT.S291611
Xu Y, Hu M, Zhang M et al (2018) Prospective study revealed prognostic significance of responses in leptomeningeal Metastasis and clinical value of cerebrospinal fluid-based liquid biopsy. Lung Cancer 125:142–149. https://doi.org/10.1016/j.lungcan.2018.08.017
Lim C, Tsao MS, Le LW et al (2015) Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell Lung cancer. Ann Oncol 26:1415–1421. https://doi.org/10.1093/annonc/mdv208
Rolfo C, Mack P, Scagliotti GV et al (2021) Liquid Biopsy for Advanced NSCLC: a Consensus Statement from the International Association for the study of Lung Cancer. J Thorac Oncol 16:1647–1662. https://doi.org/10.1016/j.jtho.2021.06.017
Bhambhvani HP, Rodrigues AJ, Umeh-Garcia MC, Hayden Gephart M (2020) Leptomeningeal Carcinomatosis: Molecular Landscape, Current Management, and emerging therapies. Neurosurg Clin N Am 31:613–625. https://doi.org/10.1016/j.nec.2020.06.010
Anwar A, Gudlavalleti A, Ramadas P (2023) Carcinomatous Meningitis. In: StatPearls. StatPearls Publishing, Treasure Island (FL)
Batool A, Kasi A (2023) Leptomeningeal Carcinomatosis. In: StatPearls. StatPearls Publishing, Treasure Island (FL)
Cescon DW, Bratman SV, Chan SM, Siu LL (2020) Circulating Tumor DNA and liquid biopsy in oncology. Nat Cancer 1:276–290. https://doi.org/10.1038/s43018-020-0043-5
Heitzer E, Ulz P, Geigl JB (2015) Circulating Tumor DNA as a liquid biopsy for cancer. Clin Chem 61:112–123. https://doi.org/10.1373/clinchem.2014.222679
Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https://doi.org/10.1136/bmj.n71
Chen X, Bai K, Zhang Y et al (2023) Genomic alterations of cerebrospinal fluid cell-free DNA in leptomeningeal metastases of gastric cancer. J Transl Med 21:296. https://doi.org/10.1186/s12967-023-04077-8
Di W-Y, Chen Y-N, Cai Y et al (2023) The diagnostic significance of cerebrospinal fluid cytology and circulating Tumor DNA in meningeal carcinomatosis. Front Neurol 14:1076310. https://doi.org/10.3389/fneur.2023.1076310
Fitzpatrick A, Iravani M, Mills A et al (2022) Assessing CSF ctDNA to improve diagnostic accuracy and therapeutic monitoring in Breast Cancer Leptomeningeal Metastasis. Clin Cancer Res 28:1180–1191. https://doi.org/10.1158/1078-0432.CCR-21-3017
Wu J, Liu Z, Huang T et al (2023) Cerebrospinal fluid circulating Tumor DNA depicts profiling of brain Metastasis in NSCLC. Mol Oncol 17:810–824. https://doi.org/10.1002/1878-0261.13357
Li M, Chen J, Zhang B et al (2023) Correction: dynamic monitoring of cerebrospinal fluid circulating Tumor DNA to identify unique genetic profiles of brain metastatic tumors and better predict intracranial Tumor responses in non-small cell Lung cancer patients with brain metastases: a prospective cohort study (GASTO 1028). BMC Med 21:15. https://doi.org/10.1186/s12916-022-02718-1
Ma C, Yang X, Xing W et al (2020) Detection of circulating Tumor DNA from non-small cell Lung cancer brain Metastasis in cerebrospinal fluid samples. Thorac Cancer 11:588–593. https://doi.org/10.1111/1759-7714.13300
Rehman AU, Khan P, Maurya SK et al (2022) Liquid biopsies to occult brain Metastasis. Mol Cancer 21:113. https://doi.org/10.1186/s12943-022-01577-x
Shtivelman E, Hensing T, Simon GR et al (2014) Molecular pathways and therapeutic targets in Lung cancer. Oncotarget 5:1392–1433. https://doi.org/10.18632/oncotarget.1891
Dar KB, Bhat AH, Amin S et al (2019) Exploring proteomic drug targets, therapeutic strategies and protein - protein interactions in Cancer: mechanistic view. Curr Cancer Drug Targets 19:430–448. https://doi.org/10.2174/1568009618666180803104631
De Mattos-Arruda L, Mayor R, Ng CKY et al (2015) Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat Commun 6:8839. https://doi.org/10.1038/ncomms9839
Sun H, Liu S-Y, Zhou J-Y et al (2020) Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma. EBioMedicine 60:102990. https://doi.org/10.1016/j.ebiom.2020.102990
Escudero L, Llort A, Arias A et al (2020) Circulating tumour DNA from the cerebrospinal fluid allows the characterisation and monitoring of medulloblastoma. Nat Commun 11:5376. https://doi.org/10.1038/s41467-020-19175-0
Escudero L, Martínez-Ricarte F, Seoane J (2021) ctDNA-Based Liquid Biopsy of Cerebrospinal Fluid in Brain Cancer. Cancers (Basel) 13:1989. https://doi.org/10.3390/cancers13091989
Funding
The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.
Author information
Authors and Affiliations
Contributions
All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed Jeremiah Hilkiah Wijaya, Utsav Dilipkumar Patel, Aulia Wiratama Putra, and Saurabh Kataria. The first draft of the manuscript was written by Jeremiah Hilkiah Wijaya and Julius July and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors have no relevant financial or non-financial interests to disclose.
Ethics approval
Not applicable.
Consent to participate
Not applicable.
Consent to publish
Not applicable.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Wijaya, J.H., Patel, U.D., Quintero-Consuegra, M.D. et al. Liquid biopsy in the setting of leptomeningeal metastases: a systematic review and meta-analysis. J Neurooncol 165, 431–438 (2023). https://doi.org/10.1007/s11060-023-04519-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-023-04519-9